Teng Lei, Bennett Edward, Cai Chuanxi
From the Center for Cardiovascular Sciences and Department of Medicine, Albany Medical College and.
Division of Cardiothoracic Surgery, Albany Medical Center, Albany, New York 12208.
J Biol Chem. 2016 Apr 29;291(18):9733-47. doi: 10.1074/jbc.M115.687806. Epub 2016 Mar 3.
Cardiac stem cell therapy has shown very promising potential to repair the infarcted heart but is severely limited by the poor survival of donor cells. Nitric oxide (NO) has demonstrated cytoprotective properties in various cells, but its benefits are unknown specifically for human cardiac stem cells (hCSCs). Therefore, we investigated whether pretreatment of hCSCs with a widely used NO donor, diethylenetriamine nitric oxide adduct (DETA-NO), promotes cell survival. Results from lactate dehydrogenase release assays showed a dose- and time-dependent attenuation of cell death induced by oxidative stress after DETA-NO preconditioning; this cytoprotective effect was abolished by the NO scavenger. Concomitant up-regulation of several cell signaling molecules after DETA-NO preconditioning was observed by Western blotting, including elevated phosphorylation of NRF2, NFκB, STAT3, ERK, and AKT, as well as increased protein expression of HO-1 and COX2. Furthermore, pharmaceutical inhibition of ERK, STAT3, and NFκB activities significantly diminished NO-induced cytoprotection against oxidative stress, whereas inhibition of AKT or knockdown of NRF2 only produced a minor effect. Blocking PI3K activity or knocking down COX2 expression did not alter the protective effect of DETA-NO on cell survival. The crucial roles of STAT3 and NFκB in NO-mediated signaling pathways were further confirmed by stable expression of gene-specific shRNAs in hCSCs. Thus, preconditioning hCSCs with DETA-NO promotes cell survival and resistance to oxidative stress by activating multiple cell survival signaling pathways. These results will potentially provide a simple and effective strategy to enhance survival of hCSCs after transplantation and increase their efficacy in repairing infarcted myocardium.
心脏干细胞疗法在修复梗死心脏方面显示出非常有前景的潜力,但受到供体细胞存活率低的严重限制。一氧化氮(NO)已在多种细胞中表现出细胞保护特性,但其对人心脏干细胞(hCSCs)的具体益处尚不清楚。因此,我们研究了用广泛使用的NO供体二乙三胺一氧化氮加合物(DETA-NO)预处理hCSCs是否能促进细胞存活。乳酸脱氢酶释放试验结果表明,DETA-NO预处理后,氧化应激诱导的细胞死亡呈剂量和时间依赖性减弱;这种细胞保护作用被NO清除剂消除。通过蛋白质印迹法观察到DETA-NO预处理后几种细胞信号分子的伴随上调,包括NRF2、NFκB、STAT3、ERK和AKT磷酸化水平升高,以及HO-1和COX2蛋白表达增加。此外,ERK、STAT3和NFκB活性的药物抑制显著减弱了NO诱导的针对氧化应激的细胞保护作用,而AKT抑制或NRF2敲低仅产生轻微影响。阻断PI3K活性或敲低COX2表达并未改变DETA-NO对细胞存活的保护作用。通过在hCSCs中稳定表达基因特异性短发夹RNA(shRNAs)进一步证实了STAT3和NFκB在NO介导的信号通路中的关键作用。因此,用DETA-NO预处理hCSCs可通过激活多种细胞存活信号通路促进细胞存活和抵抗氧化应激。这些结果可能为提高hCSCs移植后的存活率及其修复梗死心肌的疗效提供一种简单有效的策略。